Insider filing
Traded Feb 27 · filed 12 days later
Routine share withholding; mechanical by default.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 25, 2026 · Filed Feb 27, 2026
AbbVie's GC AND SECRETARY sold $5.15M of AbbVie shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$5,147,630
Shares × reported transaction price
21 days after results of Feb 4, 2026, 37 days before results of Apr 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $226.92 on Feb 25, 2026, 33% above its 52-week low and 7% below its high, after a 3% rise over the previous 30 trading days
52-week range $170.16 (Apr 21, 2025) to $244.38 (Oct 1, 2025), 76% of the way up, from 251 adjusted closes. 30 trading days earlier: $220.04 on Jan 12, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Perry C Siatis's largest sale of ABBV in their filings since 2023
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
FDA approved Venclexta on Feb 19, 2026, 6 days before this trade.
New use approved (efficacy supplement). Active ingredient: Venetoclax. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.9% | −1.2% | −1.7% |
| 30 days | −8.2% | −4.5% | −3.7% |
| 90 days | −9.1% | +10.5% | −19.6% |
| 180 days | +9.5% | +11.8% | −2.3% |
Past results only. Not a forecast.
Insider filing
Traded Feb 27 · filed 12 days later
Routine share withholding; mechanical by default.
Insider selling
Traded Mar 4 · filed 2 days laterNot reported under a pre-arranged trading plan
AbbVie's SVP, Controller sold $1.22M of AbbVie shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Feb 27 · filed 7 days later
Routine share withholding; mechanical by default.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.